Price target between $85. and $200. UBS Terminates Valeant Pharmaceuticals Intl Inc to Buy
Brokerage firm UBS Terminates its rating on Valeant Pharmaceuticals Intl Inc(NYSE:VRX). The shares have been rated Buy. The rating by UBS was issued on Mar 21, 2016.
In a different note, On Mar 21, 2016, Barclays said it Downgrades its rating on Valeant Pharmaceuticals Intl Inc. In the research note, the firm Lowers the price-target to $135.00 per share. The shares have been rated ‘Equal-weight’ by the firm. On Mar 21, 2016, Mizuho Securities said it Downgrades its rating on Valeant Pharmaceuticals Intl Inc. The shares have been rated ‘Underperform’ by the firm. On Mar 16, 2016, RBC Capital said it Maintains its rating on Valeant Pharmaceuticals Intl Inc. In the research note, the firm Lowers the price-target to $85.00 per share. The shares have been rated ‘Sector Perform’ by the firm. On Mar 16, 2016, Rodman & Renshaw said it Maintains its rating on Valeant Pharmaceuticals Intl Inc. In the research note, the firm Lowers the price-target to $150.00 per share. The shares have been rated ‘Buy’ by the firm. On Mar 16, 2016, Stifel Nicolaus said it Maintains its rating on Valeant Pharmaceuticals Intl Inc. In the research note, the firm Lowers the price-target to $200.00 per share. The shares have been rated ‘Buy’ by the firm. On Mar 16, 2016, JP Morgan said it Maintains its rating on Valeant Pharmaceuticals Intl Inc. In the research note, the firm Lowers the price-target to $200.00 per share. The shares have been rated ‘Overweight’ by the firm.
Valeant Pharmaceuticals Intl Inc(VRX) last announced its earnings results on Mar 15, 2016 for Fiscal Year 2015 and Q4.Company reported revenue of $2.79B. Analysts had an estimated revenue of $2.75B. Earnings per share were $2.50. Analysts had estimated an EPS of $2.61.
Valeant Pharmaceuticals Intl Inc (VRX) made into the market gainers list on Mondays trading session with the shares advancing 7.41% or 2 points. Due to strong positive momentum, the stock ended at $28.98, which is also near the day’s high of $31.59. The stock began the session at $26.1 and the volume stood at 7,13,32,430 shares. The 52-week high of the shares is $263.81 and the 52 week low is $25.985. The company has a current market capitalization of $9,943 M and it has 34,31,01,800 shares in outstanding.
The company shares have dropped -86.75% in the past 52 weeks.On Aug 6, 2015, the shares registered one year high of $263.81 and one year low was seen on Mar 18, 2016 at $26.72. The 50-day moving average is $74.8 and the 200 day moving averge is recorded at $116.3. S&P 500 has seen a change of -2.61% during the last 52-weeks.
Several Insider Transactions has been reported to the SEC. On Nov 9, 2015, J. Michael Pearson (Chief Executive Officer) sold 1,297,399 shares at $78.53 per share price.Also, On Oct 22, 2015, Ronald Harold Farmer (director) purchased 1,500 shares at $175.90 per share price.On Aug 3, 2015, Robert L. Rosiello (CFO) purchased 7,875 shares at $255.62 per share price, according to the Form-4 filing with the securities and exchange commission.